- Home
- AGAE vs LEXX Comparison
AGAE vs LEXX Comparison
Compare AGAE & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGAE | LEXX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 22.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AGAE | LEXX |
|---|---|---|
| Price | $0.34 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 958.0K | 135.8K |
| Earning Date | 11-19-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,938,232.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.34 | $0.77 |
| 52 Week High | $3.79 | $2.85 |
Technical Indicators
Market Signals| Indicator | AGAE | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 29.46 | 49.84 |
| Support Level | $0.34 | $1.00 |
| Resistance Level | $0.43 | $1.17 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 3.21 | 41.49 |
Price Performance
Historical ComparisonAbout AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.